|
Variables
|
N
|
%
|
|---|
|
Age
|
|
Median
|
62.5
| |
|
Quartiles
|
50.3-69
| |
|
Gender
|
|
Female VS Male
|
26:26
|
50: 50
|
|
Clinical stage
|
|
III B VS IV
|
3:49
|
5.8: 94.2
|
|
Histological diagnosis
|
|
Adenocarcinoma VS Others
|
51:1
|
98.1: 1.9
|
|
Anti-EGFR therapy
|
|
Gefitinib
|
34
|
65.4
|
|
Erlotinib
|
7
|
13.5
|
|
Ectinib
|
9
|
17.3
|
|
Ositinib
|
2
|
3.8
|
|
Other treatments
|
|
Thoracic surgery
|
2
|
4.3
|
|
Radiotherapy
|
2
|
4.3
|
|
Chemotherapy
|
39
|
82.9
|
|
Radiofrequency ablation
|
3
|
6.4
|
|
Radioactive seed implantation
|
1
|
2.1
|
|
Concomitant diseases
|
|
Arterial hypertension
|
14
|
43.7
|
|
Diabetes mellitus
|
9
|
28.1
|
|
Heart disease
|
3
|
9.4
|
|
Chronic obstructive pulmonary disease
|
3
|
9.4
|
|
Cerebral infarction
|
3
|
9.4
|
|
Smoking
|
|
Past/current
|
17
|
32.7
|
|
Never
|
35
|
67.3
|
|
D-dimer content
|
|
Decrease VS Increase
|
37:15
|
71.2: 28.8
|
|
Platelet count
|
|
Decrease VS Increase
|
33: 19
|
63.5: 36.5
|
